PMID- 25115992
OWN - NLM
STAT- MEDLINE
DCOM- 20151203
LR  - 20161125
IS  - 1522-726X (Electronic)
IS  - 1522-1946 (Linking)
VI  - 85
IP  - 4
DP  - 2015 Mar
TI  - Bivalirudin versus unfractionated heparin for residual thrombus burden: a 
      frequency-domain optical coherence tomography study.
PG  - 575-82
LID - 10.1002/ccd.25631 [doi]
AB  - OBJECTIVES: This study aimed to compare the effect of bivalirudin and 
      unfractionated heparin (UFH) on residual thrombus burden assessed by 
      frequency-domain optical coherence tomography (FD-OCT), and on angiographic 
      indices of microvascular obstruction (MVO). BACKGROUND: The efficacy of 
      bivalirudin to inhibit thrombus formation inside the stent during percutaneous 
      coronary interventions (PCI) as compared to UFH is unknown. METHODS: Sixty 
      patients with coronary artery disease who underwent post-PCI FD-OCT were studied, 
      including 20 patients treated with bivalirudin and 40 control patients treated 
      with UFH, matched by clinical presentation, stent characteristics, and 
      periprocedural medications. In-stent thrombus volume, thrombus score (number of 
      quadrants with thrombus), and thrombus type (white/red) were assessed by FD-OCT. 
      Thrombolysis in myocardial infarction (TIMI) flow grade, corrected TIMI frame 
      count (cTFC), and Quantitative Blush Evaluator (QuBE) score were recorded. 
      RESULTS: Patients treated with bivalirudin showed similar thrombus volume (0.14 
      mm(3) [0.00-0.88] vs. 0.13 mm(3) [0.00-0.63], P = 0.962), thrombus score (10 
      [0-25] vs. 8 [0-21], P = 0.849) and thrombus length (1.70 mm [0.00-4.10] vs. 1.40 
      mm [0.00-4.05], P = 0.968], as compared with patients treated with UFH. Patients 
      in the bivalirudin group showed lower proportion of white thrombus (55.5% vs. 
      78.6%, P = 0.016). There was no significant difference in TIMI flow grade, cTFC, 
      and QuBE score between the two groups. CONCLUSIONS: The present study showed 
      similar residual thrombus burden and angiographic indices of MVO immediately 
      after PCI between patients treated with bivalirudin and those treated with UFH.
CI  - (c) 2014 Wiley Periodicals, Inc.
FAU - Vergallo, Rocco
AU  - Vergallo R
AD  - Cardiology Division, Massachusetts General Hospital, Harvard Medical School, 
      Boston, Massachusetts.
FAU - Joye, Russell
AU  - Joye R
FAU - Barlis, Peter
AU  - Barlis P
FAU - Jia, Haibo
AU  - Jia H
FAU - Tian, Jinwei
AU  - Tian J
FAU - Soeda, Tsunenari
AU  - Soeda T
FAU - Minami, Yoshiyasu
AU  - Minami Y
FAU - Hu, Sining
AU  - Hu S
FAU - Dauerman, Harold L
AU  - Dauerman HL
FAU - Toma, Catalin
AU  - Toma C
FAU - Chan, James
AU  - Chan J
FAU - Lee, Hang
AU  - Lee H
FAU - Biasucci, Luigi Marzio
AU  - Biasucci LM
FAU - Crea, Filippo
AU  - Crea F
FAU - Jang, Ik-Kyung
AU  - Jang IK
LA  - eng
SI  - ClinicalTrials.gov/NCT01110538
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20140822
PL  - United States
TA  - Catheter Cardiovasc Interv
JT  - Catheterization and cardiovascular interventions : official journal of the 
      Society for Cardiac Angiography & Interventions
JID - 100884139
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Hirudins)
RN  - 0 (Peptide Fragments)
RN  - 0 (Recombinant Proteins)
RN  - 9005-49-6 (Heparin)
RN  - TN9BEX005G (bivalirudin)
SB  - IM
CIN - Catheter Cardiovasc Interv. 2015 Mar;85(4):583-4. PMID: 25702908
MH  - Aged
MH  - Controlled Clinical Trials as Topic
MH  - Coronary Angiography
MH  - Coronary Artery Disease/diagnosis/physiopathology/*therapy
MH  - Coronary Circulation
MH  - Coronary Thrombosis/diagnosis/physiopathology/*therapy
MH  - Coronary Vessels/diagnostic imaging/*pathology/physiopathology
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Heparin/*therapeutic use
MH  - Hirudins
MH  - Humans
MH  - Male
MH  - Microcirculation
MH  - Middle Aged
MH  - Peptide Fragments/*therapeutic use
MH  - *Percutaneous Coronary Intervention
MH  - Predictive Value of Tests
MH  - Recombinant Proteins/therapeutic use
MH  - Registries
MH  - Retrospective Studies
MH  - Time Factors
MH  - *Tomography, Optical Coherence
MH  - Treatment Outcome
OTO - NOTNLM
OT  - bivalirudin
OT  - optical coherence tomography
OT  - thrombus
OT  - unfractionated heparin
EDAT- 2014/08/15 06:00
MHDA- 2015/12/15 06:00
CRDT- 2014/08/14 06:00
PHST- 2014/06/20 00:00 [received]
PHST- 2014/07/23 00:00 [revised]
PHST- 2014/08/11 00:00 [accepted]
PHST- 2014/08/14 06:00 [entrez]
PHST- 2014/08/15 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - 10.1002/ccd.25631 [doi]
PST - ppublish
SO  - Catheter Cardiovasc Interv. 2015 Mar;85(4):575-82. doi: 10.1002/ccd.25631. Epub 
      2014 Aug 22.